McKesson (NYSE:MCK) Stock Gets Price Target Bump from Barclays

McKesson (NYSE:MCK – Get Free Report) had its price objective upped by investment analysts at Barclays from $1,000.00 to $1,235.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 16.22% from the company’s previous close.

MCK has been the topic of a number of other research reports. Weiss Ratings raised McKesson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Monday, November 9th. Argus boosted their price target on McKesson from $850.00 to $970.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Wells Fargo & Company upped their price objective on McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Citigroup increased their price objective on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Finally, Mizuho lifted their price objective on McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 20th. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,054.12.

Read Our Latest Research Report on McKesson

McKesson Stock Down 2.0%

NYSE:MCK opened at $1,062.62 on Wednesday. McKesson has a 52-week low of $723.68 and a 52-week high of $1,121.50. The stock has a fifty day simple moving average of $970.87 and a 200-day simple moving average of $879.62. The company has a market capitalization of $122.69 billion, a PE ratio of 25.43, a price-to-earnings-growth ratio of 1.84 and a beta of 0.27.

McKesson (NYSE:MCK – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. The firm had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The firm’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the company earned $9.86 EPS. As a group, equities analysts anticipate that McKesson will post 46.09 earnings per share for the current year.

Insiders Place Their Bets

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the sale, the chief accounting officer directly owned 521 shares of the company’s stock, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $995.80, for a total value of $796,640.00. Following the completion of the sale, the executive vice president directly owned 5,423 shares in the company, valued at approximately $5,400,223.40. The trade was a 12.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,161 shares of company stock worth $2,242,515. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On McKesson

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of McKesson in the 2nd quarter valued at $8,156,743,000. Bank of America Corp DE increased its holdings in shares of McKesson by 2.4% during the 1st quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock worth $1,331,552,000 after buying an additional 35,916 shares during the last quarter. Boston Partners increased its holdings in shares of McKesson by 1.1% during the 3rd quarter. Boston Partners now owns 1,182,796 shares of the company’s stock worth $1,014,032,000 after buying an additional 13,120 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of McKesson by 3.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock worth $697,096,000 after buying an additional 29,747 shares during the period. Finally, Legal & General Group Plc purchased a new position in shares of McKesson in the 2nd quarter worth $656,566,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

About McKesson

(Get Free Report)

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.

Featured Stories

Analyst Recommendations for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.